Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: Results of a randomized clinical trial
World Journal of Urology Feb 04, 2018
Robert G, et al. - In this trial, the efficacy and safety of Botulinum Neurotoxin Type A (BoNT-A) prostatic injection were evaluated in the individuals presenting with lower urinary tract symptoms (LUTS) because of the benign prostatic hyperperplasia. Most of the patients could interrupt LUTS-related medical treatments 4 months following BoNT-A injection. IPSS improvement was not inferior to optimized medical treatment in these patients.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
